<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73749">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742143</url>
  </required_header>
  <id_info>
    <org_study_id>12-223</org_study_id>
    <nct_id>NCT01742143</nct_id>
  </id_info>
  <brief_title>Impact of ICCAN on Cancer Treatment Completion and Quality of Life</brief_title>
  <official_title>A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The City College of New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ralph Lauren Center for Cancer Care and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lincoln Medical and Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lutheran Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this 1 year study is to see if the ICCAN program is working, and to compare
      the ICCAN program to the standard hospital services provided in New York City hospitals,
      like meeting with a Social Worker or a Patient Navigator (a person who provides personal
      hospital guidance).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Treatment completion/adherence</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome, cancer treatment completion, will be determined by chart review at 3, 6, and 12 months after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>depression, and stress (measured through validated scales included in the Cancer Treatment Outcomes</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cancer Patients</condition>
  <arm_group>
    <arm_group_label>ICCAN</arm_group_label>
    <description>For those randomized into the ICCAN arm, the core of the intervention will be three ICCAN Access Facilitators who will assess needs and synchronize for each patient an individualized set of transdisciplinary services.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual and Customary Group (U&amp;C)</arm_group_label>
    <description>Participants in this group will receive the same written materials on social and economic resources as ICCAN group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>The Integrated Cancer Care Access Network (ICCAN)</intervention_name>
    <description>Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.</description>
    <arm_group_label>ICCAN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual and Customary Group (U&amp;C)</intervention_name>
    <description>Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed.</description>
    <arm_group_label>Usual and Customary Group (U&amp;C)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible cancer patients will be recruited in person by multilingual ICCAN research
        assistants for participation in the study at Ralph Lauren Center for Cancer Care and
        Prevention (RLCCP), Lincoln Hospital (LH), and Lutheran Medical Center (LMC). In the event
        that MSKCC staff is not present when an eligible patient is identified on site,  potential
        patients may be referred to MSKCC for screening and enrollment using a Referral/Permission
        to Contact Form.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  fluent in English, Spanish, or Mandarin

          -  between the ages of 21-80 years old

          -  In the Investigator's judgment, participants must have satisfactory cognitive
             function to provide valid informed consent and participate in the ICCAN intervention.
             The Blessed Orientation-Memory Concentration test (BOMC) will be used as a cognitive
             screening tool. Patients must have a BOMC score of less than or equal to 11.

          -  cancer patients currently receiving chemotherapy (started within the past month)
             and/or radiation therapy (started within the past week), or

          -  scheduled to begin chemotherapy and/or radiation therapy within the next 2 months
             (excluding surgery only patients)

          -  planning on remaining in the area for at least 1 year

        Exclusion Criteria:

          -  diagnosed with Stage IV disease

          -  presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to
             preclude meaningful informed consent and/or data collection. (BOMC &gt;11).

          -  has another family member already enrolled in ICCAN (as determined by patient report)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesca Gany, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesca Gany, MD, MS</last_name>
    <phone>646-888-4240</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Leng, MD, MPH</last_name>
    <phone>646-888-4243</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lincoln Hospital and Mental Health Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niyati Bhagwati, MD</last_name>
      <phone>718-579-5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lutheran Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrey Saitta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Gany, MD, MS</last_name>
      <phone>646-888-4240</phone>
    </contact>
    <contact_backup>
      <last_name>Jennifer Leng, MD, MPH</last_name>
      <phone>646-888-4243</phone>
    </contact_backup>
    <investigator>
      <last_name>Francesca Gany, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ralph Lauren Center for Cancer Care and Prevention</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gina P. Villani, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Joseph Yoe, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 31, 2014</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <keyword>cancer</keyword>
  <keyword>12-223</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
